Livmoniplimab + Budigalimab + Docetaxel + Paclitaxel + Docetaxel + Paclitaxel + Gemcitabine
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Urothelial Carcinoma
Conditions
Urothelial Carcinoma
Trial Timeline
Jan 20, 2025 → Aug 1, 2028
NCT ID
NCT06632951About Livmoniplimab + Budigalimab + Docetaxel + Paclitaxel + Docetaxel + Paclitaxel + Gemcitabine
Livmoniplimab + Budigalimab + Docetaxel + Paclitaxel + Docetaxel + Paclitaxel + Gemcitabine is a phase 2 stage product being developed by AbbVie for Urothelial Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT06632951. Target conditions include Urothelial Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06632951 | Phase 2 | Active |
Competing Products
20 competing products in Urothelial Carcinoma